Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2011-004790-90 | EudraCT Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a 12-week, multi-center, open-label extension study designed to evaluate the longer-term safety, tolerability and effectiveness of lurasidone for the treatment of subjects with schizophrenia.
This is a 12-week, multi-center, open-label extension study designed to evaluate the longer-term safety, tolerability and effectiveness of lurasidone for the treatment of subjects with schizophrenia who have participated in Study D1050238, a double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance treatment of subjects with schizophrenia. Subjects who have completed the 28-week double-blind phase or who have experienced a protocol-defined relapse event during the double-blind phase of study D1050238 will have the option to participate in this study. In addition, if/when the study is discontinued by the sponsor, all subjects participating in the open-label phase and the double-blind phase of study D1050238 will have the option to participate in this extension study
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Lurasidone | Experimental | Lurasidone 40 - 80mg flexible dose |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Lurasidone | Drug | Lurasidone 40-80 mg taken orally taken once daily |
|
| Measure | Description | Time Frame |
|---|---|---|
| Safety - Treatment-emergent Adverse Events (TEAEs), TEAEs Leading to Discontinuation, and Serious AEs (SAEs) | Number of subjects with treatment-emergent adverse events (TEAEs), TEAEs leading to discontinuation, and serious AEs (SAEs) | 12 weeks |
| Efficacy - Change in Positive and Negative Syndrome Scale (PANSS) Total Score | The PANSS is an interview-based measure of the severity of psychopathology in adults with psychotic disorders. The measure is comprised of 30 items. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS total score is the sum of all 30 items and ranges from 30 through 210. A higher score is associated with greater illness severity. | Baseline to week 12 LOCF endpoint |
| Efficacy - Change From Baseline in Clinical Global Impression-Severity of Illness (CGI-S) Score. | The CGI-S score is a single value, clinician-rated assessment of illness severity and ranges from 1= 'Normal, not at all ill' to 7= 'Among the most extremely ill patients'. A higher score is associated with greater illness severity. | Baseline to week 12 LOCF endpoint |
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline in Montgomery -Asberg Depression Rating Scale Total Score | The MADRS consists of 10 items, each rated on a Likert scale, from 0="Normal" to 6="Most Severe". The MADRS total score is calculated as the sum of the 10 items. The MADRS total score ranges from 0 to 60. Higher scores are associated with greater severity. | Baseline to week 12 LOCF endpoint |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Lurasidone Medical Director, MD | Sumitomo Pharma America, Inc. | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| K and S Professional Research Services | Little Rock | Arkansas | 72201 | United States | ||
| Woodland International Research Inc. |
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Lurasidone | Lurasidone 40 - 80mg flexible dose Lurasidone: Lurasidone 40-80 mg taken orally taken once daily |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Short Form-12 Health Survey (SF-12) | The SF-12v2 is a self-administered, multipurpose short-form (SF) generic measure of health status. It was developed to be a shorter, yet valid, alternative to the SF-36 for use in large surveys of general and specific populations as well as in large longitudinal studies of health outcomes. The 12 items in the SF-12v2 are a subset of those in the SF-36; SF-12v2 includes one or two items from each of the eight health concepts with higher scores indicative of higher functioning and better health. The Physical Component Score is a composite of the Physical Functioning, Role Functioning, Bodily Pain and General Health scales. Physical Composite Scores (PCS) is computed using the scores of twelve questions and range from 0 to 100, where a zero score indicates the lowest level of health measured by the scales and 100 indicates the highest level of health. | Baseline to week 12 LOCF endpoint |
| Modified Specific Levels of Functioning (SLOF) Total Score. | The modified SLOF scale is designed to measure directly observable behavioral functioning and daily living skills of patients with chronic mental illness. The modified SLOF consists of 24 items, each item is rated on a 5-point scale and mapped to 0 to 4. The total score will be the sum of all 24 items and ranges from 0 to 96. A higher score indicates worse condition. | 12 weeks |
| Brief Adherence Rating Scale (BARS) | The Brief Adherence Rating Scale (BARS) is a clinician-administered adherence assessment instrument that consists of four items including three questions and a visual analog rating scale (VAS) to assess the percentage (0 100%) of doses taken by the subject in the previous month. | 12 weeks |
| Smoking Questionnaire | Smoking questionnaire - average number of cigarettes per day at week 12 (LOCF). | 12 weeks |
| Intent to Attend Assessment | The ITA assessment will be administered by a research staff member. The response is recorded on a 10-point scale, with 0 = "Not at all" and 9 = "Extremely". The ITA allowed the site to capture data regarding dropout risk. The following question was completed at the baseline visit: "How likely is it that you will complete the study?" | 12 weeks |
| Little Rock |
| Arkansas |
| 72211 |
| United States |
| Comprehensive Clinical Development Inc. | Cerritos | California | 90703 | United States |
| Diligent Clinical Trials | Downey | California | 90241 | United States |
| Synergy Clinical Research Center | Escondido | California | 92025 | United States |
| CNS Network | Garden Grove | California | 92845 | United States |
| AXIS Clinical Trials | Los Angeles | California | 90036 | United States |
| Synergy Clinical Research Center | National City | California | 91950 | United States |
| Excell Research, Inc. | Oceanside | California | 92056 | United States |
| CNRI-Los Angeles. LLC | Pico Rivera | California | 90660 | United States |
| California Neuropsychopharmacolgoy Clinical Research Insitute | San Diego | California | 92126 | United States |
| Neuropsychiatric Research Center of Orange County | Santa Ana | California | 92701 | United States |
| Collaborative Neuroscience Network | Torrance | California | 90502 | United States |
| Florida Clinical Research Center, LLC | Bradenton | Florida | 34208 | United States |
| Accurate Clinical Trials | Kissimmee | Florida | 34742 | United States |
| Galiz Research | Miami Springs | Florida | 33166 | United States |
| Medical Research Group of Central Florida | Orange City | Florida | 32763 | United States |
| Atlanta Center for Medical Research | Atlanta | Georgia | 30308 | United States |
| Comprehensive NeuroScience Inc. | Atlanta | Georgia | 30328 | United States |
| Lake Charles Clinical Trials, LLC | Lake Charles | Louisiana | 70601 | United States |
| Lousiana Clinical Research, LLC | Shreveport | Louisiana | 71104 | United States |
| Center for Behavioral Health, LLC | Rockville | Maryland | 20850 | United States |
| Psychiatric Care and Research Center | O'Fallon | Missouri | 63368 | United States |
| Psych Care Consultants Research | St Louis | Missouri | 63128 | United States |
| Robert Lynn Horne, MD | Las Vegas | Nevada | 89102 | United States |
| CRI Worldwide LLC | Willingboro | New Jersey | 08046 | United States |
| Erie County Medical Center, Corp | Buffalo | New York | 14215 | United States |
| Neurobehavioral Research Inc. | Cedarhurst | New York | 11516 | United States |
| Comprehensive Clinical Development, Inc | Fresh Meadows | New York | 11366 | United States |
| Finger Lakes Clinical Research | Rochester | New York | 14618 | United States |
| Oklahoma Clinical Research | Oklahoma City | Oklahoma | 73116 | United States |
| CRI Worldwide LLC at Kirkbride | Philadelphia | Pennsylvania | 19139 | United States |
| Lincoln Research | Lincoln | Rhode Island | 02865 | United States |
| Community Clinical Research, Inc. | Austin | Texas | 78754 | United States |
| FutureSearch Clinical Trials LP | Austin | Texas | 78756 | United States |
| FutureSearch Clinical Trials, LP | Dallas | Texas | 75231 | United States |
| Pillar Clinical Research, LLC | Dallas | Texas | 75243 | United States |
| Department of Psychiatry, University of Utah Health Sciences Center | Salt Lake City | Utah | 84132 | United States |
| Centre Hospitalier Spécialisé (CHS) du Jura - Centre Médico Psychiatrique (CMP) | Dole | 39100 | France |
| Hôpital Chalucet, Centre hospitalier intercommunal de Toulon la Seyne sur mer (CHITS) | Toulon | 83000 | France |
| Dipartimento Salute Mentale ASL 1 | Massa | 54100 | Italy |
| A.O.U. Santa Chiara, U.O di Psichiatria 1 building n.4 | Pisa | 56100 | Italy |
| Regional Government Institution (RGI) 'Lipetsk Regional Psychoneurology Hospital' | Lipetsk | 398007 | Russia |
| Limited Liability Company (LLC) 'Research Center For Treatment and rehabilitation 'Phoenix' | Rostov-on-Don | 344000 | Russia |
| St. Petersburg State Healthcare Institution (SPbSHI) "City Psychiatric Hospital #6" | Saint Peterburg | 191167 | Russia |
| St. Petersburg State Budgetary Healthcare Institution 'City Psychoneurology Dispensary #7 (with In-Patient Department)', (SPb SBHI "CPNDD-7") | Saint Petersburg | 190005 | Russia |
| St. Petersburg State Budgetary Healthcare Institution 'City Psychoneurology Dispensary #7 (with In-Patient Department)', (SPb SBHI "CPNDD-7"), at Daycare Facility #1 | Saint Petersburg | 19005 | Russia |
| St. Petersburg State Government Healthcare Institution "City Psychiatric Hospital #4" (St. Petersburg Insane Asylum Distributor) | Saint Petersburg | 191119 | Russia |
| Military Medical Academy, Clnic for Psychiatry | Belgrade | 11000 | Serbia |
| Institute of Mental Health | Dusica | 11000 | Serbia |
| Clinical Centre Kragujevac, Clinic for psychiatry | Kragujevac | 34000 | Serbia |
| Clinical Centre Nis, Clinic for mental health protection | Niš | 18000 | Serbia |
| Specialized hospital for psychiatric diseases "Sveti Vracevi" | Novi Kneževac | 23330 | Serbia |
| Clinical Centre Vojvodine, Clinic for Psychiatry | Novi Sad | 21000 | Serbia |
| Nemocnica s poliklinikou v Prievidzi so sidlom v Bojniciach, Psychiatricke oddelenie | Bojnice | 972 01 | Slovakia |
| Psychiatricka ambulancia Mentum s.r.o. | Bratislava | 82007 | Slovakia |
| Psychiatricka nemocnica Michalovce n.o. | Michalovce | 071 01 | Slovakia |
| PsychoLine s.r.o. Psychiatricka ambulancia | Rimavská Sobota | 97901 | Slovakia |
| Nemocnica s poliklinikou sv Barbory Roznava a.s. Psychiatricke oddelenie | Rožňava | 048 01 | Slovakia |
| "Centrum zdravia R.B.K., spol. s.r.o. | Svidník | 089 01 | Slovakia |
| Cape Trial Centre | Tygervalley | Western Cape | 7530 | South Africa |
| Research Unit, Department of Psychiatry Free State Psychiatric Complex | Bloemfontein | 9300 | South Africa |
| Denmar Hospital Consulting Rooms | Pretoria | 0081 | South Africa |
| COMPLETED |
|
| NOT COMPLETED |
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Lurasidone | Lurasidone 40 - 80mg flexible dose Lurasidone: Lurasidone 40-80 mg taken orally taken once daily |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | Years |
| ||||||||||||||||||||||
| Age, Categorical | Count of Participants | Participants |
| |||||||||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| |||||||||||||||||||||||
| Region of Enrollment | Number | participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Safety - Treatment-emergent Adverse Events (TEAEs), TEAEs Leading to Discontinuation, and Serious AEs (SAEs) | Number of subjects with treatment-emergent adverse events (TEAEs), TEAEs leading to discontinuation, and serious AEs (SAEs) | Posted | Number | participants | 12 weeks |
|
|
| |||||||||||||||||||||||||||||||||||||
| Primary | Efficacy - Change in Positive and Negative Syndrome Scale (PANSS) Total Score | The PANSS is an interview-based measure of the severity of psychopathology in adults with psychotic disorders. The measure is comprised of 30 items. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS total score is the sum of all 30 items and ranges from 30 through 210. A higher score is associated with greater illness severity. | Posted | Mean | Standard Deviation | units on a scale | Baseline to week 12 LOCF endpoint |
|
| |||||||||||||||||||||||||||||||||||||
| Primary | Efficacy - Change From Baseline in Clinical Global Impression-Severity of Illness (CGI-S) Score. | The CGI-S score is a single value, clinician-rated assessment of illness severity and ranges from 1= 'Normal, not at all ill' to 7= 'Among the most extremely ill patients'. A higher score is associated with greater illness severity. | Posted | Mean | Standard Deviation | units on a scale | Baseline to week 12 LOCF endpoint |
|
| |||||||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline in Montgomery -Asberg Depression Rating Scale Total Score | The MADRS consists of 10 items, each rated on a Likert scale, from 0="Normal" to 6="Most Severe". The MADRS total score is calculated as the sum of the 10 items. The MADRS total score ranges from 0 to 60. Higher scores are associated with greater severity. | Only 182 subjects had post-baseline MADRS assessments. | Posted | Mean | Standard Deviation | units on a scale | Baseline to week 12 LOCF endpoint |
|
| ||||||||||||||||||||||||||||||||||||
| Secondary | Short Form-12 Health Survey (SF-12) | The SF-12v2 is a self-administered, multipurpose short-form (SF) generic measure of health status. It was developed to be a shorter, yet valid, alternative to the SF-36 for use in large surveys of general and specific populations as well as in large longitudinal studies of health outcomes. The 12 items in the SF-12v2 are a subset of those in the SF-36; SF-12v2 includes one or two items from each of the eight health concepts with higher scores indicative of higher functioning and better health. The Physical Component Score is a composite of the Physical Functioning, Role Functioning, Bodily Pain and General Health scales. Physical Composite Scores (PCS) is computed using the scores of twelve questions and range from 0 to 100, where a zero score indicates the lowest level of health measured by the scales and 100 indicates the highest level of health. | Only 182 subjects had post-baseline SF-12.v2 assessments. | Posted | Mean | Standard Deviation | units on a scale | Baseline to week 12 LOCF endpoint |
|
| ||||||||||||||||||||||||||||||||||||
| Secondary | Modified Specific Levels of Functioning (SLOF) Total Score. | The modified SLOF scale is designed to measure directly observable behavioral functioning and daily living skills of patients with chronic mental illness. The modified SLOF consists of 24 items, each item is rated on a 5-point scale and mapped to 0 to 4. The total score will be the sum of all 24 items and ranges from 0 to 96. A higher score indicates worse condition. | Only 174 subjects had SLOF assessments at week 12 LOCF. | Posted | Mean | Standard Deviation | units on a scale | 12 weeks |
|
| ||||||||||||||||||||||||||||||||||||
| Secondary | Brief Adherence Rating Scale (BARS) | The Brief Adherence Rating Scale (BARS) is a clinician-administered adherence assessment instrument that consists of four items including three questions and a visual analog rating scale (VAS) to assess the percentage (0 100%) of doses taken by the subject in the previous month. | Posted | Mean | Standard Deviation | percentage of monthly doses taken | 12 weeks |
|
| |||||||||||||||||||||||||||||||||||||
| Secondary | Smoking Questionnaire | Smoking questionnaire - average number of cigarettes per day at week 12 (LOCF). | Only 36 subjects who were smokers had the smoker questionnaire assessments. | Posted | Mean | Standard Deviation | number of cigarettes smoked daily | 12 weeks |
|
| ||||||||||||||||||||||||||||||||||||
| Secondary | Intent to Attend Assessment | The ITA assessment will be administered by a research staff member. The response is recorded on a 10-point scale, with 0 = "Not at all" and 9 = "Extremely". The ITA allowed the site to capture data regarding dropout risk. The following question was completed at the baseline visit: "How likely is it that you will complete the study?" | Only 1825 subjects answered the questionnaire. | Posted | Mean | Standard Deviation | units on a scale | 12 weeks |
|
|
12 Weeks
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Lurasidone | Lurasidone 40 - 80mg flexible dose Lurasidone: Lurasidone 40-80 mg taken orally taken once daily | 13 | 191 | 34 | 191 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Artrial flutter | Cardiac disorders | MedDRA (15.0) | Systematic Assessment |
| |
| Chest Pain | General disorders | MedDRA (15.0) | Systematic Assessment |
| |
| Pneumonia | Infections and infestations | MedDRA (15.0) | Systematic Assessment |
| |
| Schizophrenia | Psychiatric disorders | MedDRA (15.0) | Systematic Assessment |
| |
| Psychotic Disorder | Psychiatric disorders | MedDRA (15.0) | Systematic Assessment |
| |
| Hypotension | Vascular disorders | MedDRA (15.0) | Systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Diarrhoea | Gastrointestinal disorders | MedDRA (15.0) | Systematic Assessment |
| |
| Nausea | Gastrointestinal disorders | MedDRA (15.0) | Systematic Assessment |
| |
| Nasopharyngitis | Infections and infestations | MedDRA (15.0) | Systematic Assessment |
| |
| Akathisia | Nervous system disorders | MedDRA (15.0) | Systematic Assessment |
| |
| Headache | Nervous system disorders | MedDRA (15.0) | Systematic Assessment |
| |
| Schizophrenia | Psychiatric disorders | MedDRA (15.0) | Systematic Assessment |
| |
| Anxiety | Psychiatric disorders | MedDRA (15.0) | Systematic Assessment |
| |
| Insomnia | Psychiatric disorders | MedDRA (15.0) | Systematic Assessment |
|
There IS agreement between Principal Investigator and Sponsor that restricts PI's rights to discuss or publish trial results after trial is completed.
In addition to the <60-180 day restriction above, since this is a multicenter study, 1st publication of study results shall be made with other participating study sites as a multicenter publication provided, if a multicenter publication is not forthcoming within 24 months post completion of study at all sites, PI shall be free to publish.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Medical Director CNS Clinical Trials | Sunovion | 1-866-503-6351 | clinicaltrialdisclosure@sunvion.com |
| ID | Term |
|---|---|
| D012559 | Schizophrenia |
| ID | Term |
|---|---|
| D019967 | Schizophrenia Spectrum and Other Psychotic Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D000069056 | Lurasidone Hydrochloride |
| ID | Term |
|---|---|
| D013844 | Thiazoles |
| D013457 | Sulfur Compounds |
| D009930 | Organic Chemicals |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D054833 | Isoindoles |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
Not provided
Not provided
| >=65 years |
|
| United States |
|
| Slovakia |
|
| Russia |
|
| South Africa |
|
| Title | Measurements |
|---|---|
|
|
| Title | Denominators | Categories | ||||
|---|---|---|---|---|---|---|
|
|
|
|
| Title | Denominators | Categories | ||||
|---|---|---|---|---|---|---|
|
| Title | Denominators | Categories | ||||
|---|---|---|---|---|---|---|
|
|